Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Repare Therapeutics Inc (NQ: RPTX ) 2.930 -0.070 (-2.33%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 16, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 81,097 Open 2.970 Bid (Size) 2.920 (17) Ask (Size) 2.950 (4) Prev. Close 3.000 Today's Range 2.910 - 3.060 52wk Range 2.780 - 13.85 Shares Outstanding 42,088,446 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Repare Therapeutics Provides Business and Clinical Update and Reports Second Quarter 2024 Financial Results August 06, 2024 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRI June 26, 2024 From Repare Therapeutics Inc. Via Business Wire Performance YTD -59.81% -59.81% 1 Month -25.63% -25.63% 3 Month -15.80% -15.80% 6 Month -53.34% -53.34% 1 Year -71.75% -71.75% More News Read More Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical Trial June 10, 2024 From Repare Therapeutics Inc. Via Business Wire Recap: Repare Therapeutics Q4 Earnings February 28, 2024 Via Benzinga Repare Therapeutics Announces Fast Track Designation Granted by the FDA for Lunresertib in Combination with Camonsertib for the Treatment of Platinum-Resistant Ovarian Cancer June 04, 2024 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference June 03, 2024 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics to Present Initial Phase 1 MINOTAUR Data at ESMO GI Congress 2024 May 29, 2024 From Repare Therapeutics Inc. Via Business Wire Why RingCentral Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket May 08, 2024 Via Benzinga Why Upstart Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session May 08, 2024 Via Benzinga 12 Health Care Stocks Moving In Wednesday's Pre-Market Session May 08, 2024 Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday May 08, 2024 Via InvestorPlace RPTX Stock Earnings: Repare Therapeutics Beats EPS, Beats Revenue for Q1 2024 May 07, 2024 Via InvestorPlace Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results May 07, 2024 From Repare Therapeutics Inc. Via Business Wire Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1b Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1 AND PKMYT1 Inhibition April 30, 2024 From Debiopharm Via Business Wire Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition April 30, 2024 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics Appoints Steven H. Stein, M.D. to its Board of Directors April 26, 2024 From Repare Therapeutics Inc. Via Business Wire Roche's Lymphoma Drug With Chemo Extends Survival In Pretreated Patients April 15, 2024 Via Benzinga Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings March 21, 2024 From Bronstein, Gewirtz & Grossman, LLC Via Business Wire Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings March 15, 2024 From Bronstein, Gewirtz & Grossman, LLC Via Business Wire Repare Therapeutics to Participate in Two Upcoming Investor Conferences February 29, 2024 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results February 28, 2024 From Repare Therapeutics Inc. Via Business Wire REPARE ALERT: Bragar Eagel & Squire, P.C. is Investigating Repare Therapeutics Inc. on Behalf of Repare Stockholders and Encourages Investors to Contact the Firm February 20, 2024 From Bragar Eagel & Squire Via GlobeNewswire Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Repare Therapeutics Inc. (RPTX) February 16, 2024 From Kirby McInerney LLP Via Business Wire Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664 February 15, 2024 From Repare Therapeutics Inc. Via Business Wire Roche Terminates Cancer Drug Pact With Repare Therapeutics, Its Second Walkout Within A Month February 13, 2024 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.